Biotech

All Articles

Alnylam abandons clinical-stage Type 2 diabetes mellitus asset

.Alnylam is actually putting on hold even further advancement of a clinical-stage RNAi restorative d...

Takeda ceases period 2 sleep apnea test over slow application

.Takeda has ceased (PDF) a phase 2 trial of danavorexton due to slow enrollment, noting one more var...

Compass delays period 3 experimental information, gives up 30% of team

.Compass Pathways' trip to stage 3 experimental clinical depression data is taking much longer than ...

Former Seagen CEO reveals brand new start-up Ottimo Pharma

.After antibody-drug conjugate (ADC) professional Seagen was actually marketed to Pfizer last year f...

Ironwood creates further bid for $1B GI medicine along with brand new subgroup information

.On the heels of a period 3 succeed that stopped working to wow capitalists, Ironwood Pharmaceutical...

Novartis inks $150M package for autoimmune molecular glue

.Don't cease Monte Rosa Therapies right now. The Boston-based biotech is actually enjoying after sig...

Jade carves out officer group along with Chinook vets-- Chutes &amp Ladders

.Welcome to today's Chutes &amp Ladders, our roundup of notable leadership hirings, firings and also...

Septerna goes social along with upsized offering of $288M

.Commemorating his business's upsized initial public offering (IPO), Septerna chief executive office...

AbbVie brings in Richter wealthier, paying out $25M to constitute invention pact

.AbbVie has come back to the resource of its antipsychotic goliath Vraylar looking for an additional...

GenSight gets into last weeks of cash money path as profits flow squeezes by of reach

.GenSight Biologics is full weeks away from lacking money. Again. The biotech merely possesses enoug...